Class summary at a glance.

Every drug in the Rifamycin Antimycobacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $11.2Mcombined across class
Total Rx claims: 30K15K unique beneficiaries
Generic mfrs (active): 1across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Rifabutin

25K Part D claims (CY24) · 12K beneficiaries · First FDA approval: 2014-04-07

1 generic mfrs 0 plans require PA

Low NADAC$9.18

→

Avg plan cost$9.18

Part D spend $10.4M 1× spread, current vs floor

Class share

93%

of class CY24 spend

View profile →

Rifapentine

Brand: Priftin · 4K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2017-02-08

Brand-only (no generics) 0 plans require PA Active FDA shortage

Low NADAC$4.85

→

Avg plan cost$4.85

Part D spend $818510 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Omeprazole Magnesium, Amoxicillin and Rifabutin

Brand: Talicia · — Part D claims (CY24) · First FDA approval: 2020-03-09

Brand-only (no generics) 0 plans require PA

Low NADAC$4.86

→

Avg plan cost$4.86

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.